Communiqués Revvity, Inc.

Actions

RVTY

US7140461093

Equipement et technologie médicale avancés

Marché Fermé - NYSE Autres places de cotation 22:00:02 21/07/2026			Pré-ouverture 13:25:36
110,52 ^USD	+3,83%		106,14	-3,96%

21/07	Danaher : la révision à la baisse des perspectives de revenus et la déception dans les biotechnologies éclipsent le relèvement des prévisions de bénéfices	RE
15/07	REVVITY, INC. : TD Cowen reste à l'achat	ZM

Communiqués

20/07	Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure	BU
08/07	Revvity to Hold Earnings Call on Tuesday, August 4, 2026	BU
01/07	Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration	BU
22/06	Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D	BU
08/05	Revvity : First Quarter 2026 Transcript	PU
05/05	Revvity: Q1 Earnings Snapshot	AQ
05/05	Revvity : First Quarter 2026 Non-GAAP Reconciliations	PU
05/05	Revvity Announces Financial Results for the First Quarter of 2026	BU
30/04	Revvity Board Declares Quarterly Dividend	BU
17/04	Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026	AQ
16/04	Revvity to Present at Upcoming Investor Conferences	BU
13/04	Revvity to Hold Earnings Call on Tuesday, May 5, 2026	AQ
10/04	Revvity to Hold Earnings Call on Tuesday, May 5, 2026	BU
09/04	Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows	BU
24/02	Revvity : Annual Report for Fiscal Year Ending 12/28, 2025 (Form 10-K)	PU
17/02	Revvity to Present at Upcoming Investor Conferences	BU
05/02	Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026	BU
02/02	Revvity : Q4 2025 Revvity Earnings Conference Call Presentation	PU
02/02	Revvity: Q4 Earnings Snapshot	AQ
02/02	Revvity : Fourth Quarter 2025 Non-GAAP Reconciliations	PU
02/02	Revvity : Fourth Quarter 2025 Earnings Presentation	PU
02/02	Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025	BU
26/01	Revvity Board Declares Quarterly Dividend	BU
12/01	Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance	BU
12/01	Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models	AQ